Iovance Biotherapeutics Inc (NASDAQ:IOVA) traded at $14.03 at close of the session on Monday, March 18, made an upward move of 0.86% on its previous day’s price.
Looking at the stock we see that its previous close was $13.91 and the beta (5Y monthly) reads 0.62 . In terms of its 52-week price range, IOVA has a high of $18.33 and a low of $3.21. The company’s stock has gained about 42.15% over that past 30 days.
Iovance Biotherapeutics Inc has a market cap of $3.92 billion and is expected to release its quarterly earnings report on May 07, 2024 – May 13, 2024. Estimates by analysts give the company expected earnings per share (EPS) of -$0.42, with the EPS growth for the year raised at -$1.29 for 2024 and -$0.71 for next year. These figures represent 31.70% and 45.00% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $2.07 million, with a low of $480k and a high of $6 million. The median projection represents growth squeezing down to 935.00% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2024 is expected to hit $162.27 million, or 13,547.60% up from figures reported last year.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the IOVA stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Looking further, we note the current price level is -9.03% off its SMA20 and 24.54% from its 50-day simple moving average. The RSI (14) is pointing at 51.11 while the volatility over the past week is 5.72% and jumps to 10.18% over the past one month. The beta value is 0.63, while the average true range (ATR) is currently pointing at 1.18.
Coming back to Iovance Biotherapeutics Inc (NASDAQ:IOVA), we note that the average 3-month trading volume was 10.71 million, while that of the preceding 10-day period stands at 8.82 million. Current shares outstanding are 256.14 million.
The insiders hold 21.24% of the company’s shares while institutions hold 67.26%. The data shows that short shares as of Feb 29, 2024, stood at 46.71 million at a short ratio of 3.33. This represents a 16.72% short interest in shares outstanding on Feb 29, 2024. Shares short rose in February from the previous month at 41.97 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 72.57% up in year-to-date price movement.
